Yifan Pharmaceutical (SHE:002019) subsidiary Suzhou Yifan secured a winning bid for its Qiangli Pipalu (strong loquat syrup) in the national centralized procurement of Chinese patent medicines.
The product, used for bronchitis-related cough, will be supplied under a procurement cycle running through Dec. 31, 2028, according to a Monday filing with the Shenzhen bourse.
Shares of the pharmaceutical company climbed 1% in recent trade.